UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.
Search Articles
Molecular cancer therapeutics, ISSN 1535-7163, 03/2016, Volume 15, Issue 3, pp. 439 - 447
AURISTATIN-E CONJUGATE | DIAGNOSIS | POTENT | MARKER | CARCINOMAS | MONOCLONAL-ANTIBODY | ANTITUMOR-ACTIVITY | EXPRESSION | BINDING | CHEMOTHERAPY | Life Sciences & Biomedicine | Oncology | Science & Technology | Immunohistochemistry | Humans | Middle Aged | Ovarian Neoplasms - pathology | Drug Resistance, Neoplasm | Tomography, X-Ray Computed | Antineoplastic Agents - therapeutic use | Ovarian Neoplasms - mortality | Molecular Targeted Therapy | Immunoconjugates - pharmacology | Immunoconjugates - therapeutic use | Adult | Female | Antineoplastic Agents - pharmacology | Ovarian Neoplasms - metabolism | GPI-Linked Proteins - antagonists & inhibitors | Ovarian Neoplasms - drug therapy | Platinum - therapeutic use | Drug Administration Schedule | Treatment Outcome | Disease Progression | Retreatment | Biomarkers | Aged | Neoplasm Staging | Index Medicus
Journal Article
Expert opinion on investigational drugs, ISSN 1354-3784, 05/2017, Volume 26, Issue 5, pp. 541 - 550
Early clinical trials | non-small cell lung cancer | Hsp70 inhibitors | Hsp90 inhibitors | Hsp27 inhibitors | ADVANCED SOLID TUMORS | ACQUIRED-RESISTANCE | HSP90 INHIBITOR GANETESPIB | I DOSE-ESCALATION | CELL LUNG-CANCER | TYROSINE KINASE INHIBITORS | POTENT ANTITUMOR-ACTIVITY | GROWTH-FACTOR RECEPTOR | OCULAR TOXICITY | PHASE-I | Life Sciences & Biomedicine | Pharmacology & Pharmacy | Science & Technology | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - drug therapy | HSP70 Heat-Shock Proteins - antagonists & inhibitors | Humans | Heat-Shock Proteins - antagonists & inhibitors | Lung Neoplasms - pathology | Patient Selection | Animals | HSP90 Heat-Shock Proteins - antagonists & inhibitors | Drug Design | Antineoplastic Agents - pharmacology | HSP27 Heat-Shock Proteins - antagonists & inhibitors | Carcinoma, Non-Small-Cell Lung - drug therapy | Neoplasm Staging | Index Medicus
Journal Article
Endocrine reviews, ISSN 0163-769X, 08/2006, Volume 27, Issue 5, pp. 535 - 560
PROTOONCOGENE POINT MUTATIONS | POTENT ANTITUMOR-ACTIVITY | MEDULLARY-THYROID-CARCINOMA | GROWTH-FACTOR RECEPTOR | CODON 918 MUTATION | GERMLINE-SEQUENCE VARIANTS | NEOPLASIA TYPE 2A | FOCAL-ADHESION KINASE | 3-KINASE/AKT SIGNALING PATHWAY | UMCG Approved | RECEPTOR TYROSINE KINASE | Life Sciences & Biomedicine | Endocrinology & Metabolism | Science & Technology | Fundamental and applied biological sciences. Psychology | Vertebrates: endocrinology | Biological and medical sciences | Haplotypes | Gene Targeting | Genetic Therapy | Multiple Endocrine Neoplasia Type 2a - diagnosis | Endocrine Gland Neoplasms - genetics | Humans | Polymorphism, Genetic | Endocrine Gland Neoplasms - therapy | Animals | Proto-Oncogene Proteins c-ret - physiology | Signal Transduction - drug effects | Models, Biological | Endocrine Gland Neoplasms - diagnosis | Ligands | Multiple Endocrine Neoplasia Type 2a - therapy | Fetal Development - genetics | Multiple Endocrine Neoplasia Type 2a - genetics | Proto-Oncogene Proteins c-ret - antagonists & inhibitors | Proto-Oncogene Proteins c-ret - genetics | Index Medicus
Journal Article
Drug resistance updates, ISSN 1368-7646, 2005, Volume 8, Issue 6, pp. 381 - 402
Therapeutic proteins | Angiogenesis | Gene delivery | Arg-Gly-Asp | Drug delivery | Antivascular therapies | Polymers | Radiotracer | RGD | Endothelial cells | Cytostatic drugs | Cancer | endothelial cells | VITRONECTIN RECEPTOR ANTAGONIST | SNAKE-VENOM DISINTEGRINS | angiogenesis | NECROSIS-FACTOR-ALPHA | drug delivery | UMCG Approved | therapeutic proteins | CANCER ALPHA(V)-INTEGRIN EXPRESSION | gene delivery | POTENT ANTITUMOR-ACTIVITY | CONDITIONALLY REPLICATIVE ADENOVIRUSES | POSITRON-EMISSION-TOMOGRAPHY | radiotracer | cytostatic drugs | ALPHA(V)BETA INTEGRIN ANTAGONISTS | VIRUS-LIKE PARTICLES | cancer | antivascular therapies | polymers | Life Sciences & Biomedicine | Pharmacology & Pharmacy | Science & Technology | Neoplasms - metabolism | Recombinant Proteins - therapeutic use | Tumor Necrosis Factor-alpha - metabolism | Doxorubicin - therapeutic use | Genetic Therapy | RNA, Small Interfering - genetics | Humans | Tumor Necrosis Factor-alpha - genetics | Antineoplastic Agents - therapeutic use | Neoplasms - diagnosis | Vascular Endothelial Growth Factor A - metabolism | Vascular Endothelial Growth Factor A - genetics | Drug Carriers - chemistry | Integrin alphaVbeta3 - metabolism | Peptides, Cyclic - metabolism | Oligopeptides - therapeutic use | Antineoplastic Agents - metabolism | Transfection | Neoplasms - genetics | Doxorubicin - analogs & derivatives | Doxorubicin - metabolism | Oligopeptides - chemistry | Polyethylene Glycols - metabolism | Recombinant Proteins - metabolism | Endothelial Cells - metabolism | Oligopeptides - genetics | Genetic Vectors - metabolism | Clinical Trials as Topic | Oligopeptides - metabolism | Genetic Vectors - genetics | Neoplasms - drug therapy | Integrin alphaVbeta3 - analysis | Tumor Necrosis Factor-alpha - therapeutic use | Animals | Mutation | RNA, Small Interfering - metabolism | Proteins | Drugs | Drug delivery systems | Care and treatment | Peptides | Radioactive tracers | Health aspects | Tumors | Vehicles | Index Medicus
Journal Article
Molecular Cancer Therapeutics, ISSN 1535-7163, 11/2006, Volume 5, Issue 11, pp. 2644 - 2658
potent in vitro and in vivo preclinical antitumor activity | in phase I clinical trials | CDK selective inhibitor | Life Sciences & Biomedicine | Oncology | Science & Technology | Cyclin-Dependent Kinases - metabolism | Humans | Rats, Inbred F344 | Retinoblastoma - drug therapy | Antineoplastic Agents - therapeutic use | G1 Phase - drug effects | G2 Phase - drug effects | Female | Antineoplastic Agents - pharmacokinetics | Antineoplastic Agents - pharmacology | Cyclin-Dependent Kinases - antagonists & inhibitors | Genes, MDR - drug effects | Phosphorylation - drug effects | Tumor Suppressor Protein p53 - metabolism | Rats | Pyrimidines - pharmacology | Retinoblastoma - metabolism | Animals | Mice, Nude | Pyrimidines - therapeutic use | Cell Line, Tumor | Pyrimidines - pharmacokinetics | Cell Proliferation - drug effects | Mice | Clinical Trials, Phase I as Topic | Apoptosis | Index Medicus
Journal Article
Heterocycles, ISSN 0385-5414, 12/2000, Volume 53, Issue 12, pp. 2719 - 2737
Journal Article
10/2009, ISBN 0470278293, 24
AZD 1152 discovery ‐ selective inhibitor of Aurora‐B kinase with potent antitumor activity | quinazolines substituted with aminothiazoles | screening cascade updated | AZD 1152 discovery-selective inhibitor of Aurora-B kinase with potent antitumor activity | Quinazolines substituted with aminothiazoles | Screening cascade updated
Book Chapter
Journal of the Brazilian Chemical Society, ISSN 0103-5053, 2011, Volume 22, Issue 5, pp. 961 - 967
Journal Article